tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Troppmann C et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. 2003 Transplantation pmid:12883205
Therapondos G et al. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? 2003 Transplantation pmid:12883220
Ogunseinde BA et al. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. 2003 Transplantation pmid:12883222
Andrades KM et al. Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. 2013 Transplantation pmid:23380869
Adams PS et al. Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. 2013 Transplantation pmid:23380870
Ellis D et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. 1999 Transplantation pmid:10532541
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Leroy-Matheron C et al. Inhibitor against coagulation factor V after liver transplantation. 1999 Transplantation pmid:10532550
Boleslawski E et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. 2004 Transplantation pmid:15223897
Hostettler KE et al. Cyclosporine A mediates fibroproliferation through epithelial cells. 2004 Transplantation pmid:15223908
Yang CW et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. 2003 Transplantation pmid:12544865
Rodrigo E et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. 2016 Transplantation pmid:26703349
Reutzel-Selke A et al. Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. 2003 Transplantation pmid:12811235
Molano RD et al. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. 2003 Transplantation pmid:12811239
Bilolo KK et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. 2003 Transplantation pmid:12811249
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Waldman WJ et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. 2001 Transplantation pmid:11707749
Miroux C et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. 2012 Transplantation pmid:22743548
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Jindal RM et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. 1993 Transplantation pmid:7504347
Jeske HC et al. Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. 2003 Transplantation pmid:14557751
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Welberry Smith MP et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. 2013 Transplantation pmid:24056618
Papadopoulos-Köhn A et al. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. 2015 Transplantation pmid:25208324
Jain A et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. 2001 Transplantation pmid:11579306
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
de Graav GN et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. 2017 Transplantation pmid:28403127
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Egidi MF and Gaber AO Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2003 Transplantation pmid:12605133
Thervet E et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. 2003 Transplantation pmid:14578760
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Watanabe M et al. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. 2013 Transplantation pmid:23860082
Zhao WY et al. Single kidneys transplanted from small pediatric donors less than 15 kilograms into pediatric recipients. 2014 Transplantation pmid:25955345
Burroughs TE et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. 2009 Transplantation pmid:19667939
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Jurcevic S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. 1998 Transplantation pmid:9603168
Kung L and Halloran PF Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. 2000 Transplantation pmid:10933159
Beatty PR et al. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. 1998 Transplantation pmid:9603175
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Maes BD et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. 1999 Transplantation pmid:10589943
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Shapiro AM et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. 2002 Transplantation pmid:12490784
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Mehra MR et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. 2002 Transplantation pmid:12490790
Tokita D et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. 2008 Transplantation pmid:18301333
Niioka T et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. 2012 Transplantation pmid:23073468
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Swinnen LJ et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. 2008 Transplantation pmid:18645482
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Singla AK et al. Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. 2014 Transplantation pmid:24949498
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Sommerer C et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. 2010 Transplantation pmid:20463649
Walsh C et al. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. 2013 Transplantation pmid:23296149
Froud T et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. 2008 Transplantation pmid:19104407
Tan HP et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. 2008 Transplantation pmid:19104412
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
de Fijter JW Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? 2011 Transplantation pmid:21654351
Brunet M et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. 2006 Transplantation pmid:16495801
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Reyes J et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. 2000 Transplantation pmid:10910279
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Yamauchi A et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. 2002 Transplantation pmid:12352921
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Borni-Duval C et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. 2013 Transplantation pmid:23778568
Ekser B et al. Hepatic function after genetically engineered pig liver transplantation in baboons. 2010 Transplantation pmid:20606605
van Boekel GA et al. Effect of mild diarrhea on tacrolimus exposure. 2012 Transplantation pmid:22955188
Mourer JS et al. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. 2012 Transplantation pmid:22955227
Radkowski M et al. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. 1998 Transplantation pmid:9753352
Ciancio G et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. 2004 Transplantation pmid:14742989
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. 2004 Transplantation pmid:14742990
van Hooff JP et al. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. 2005 Transplantation pmid:15940032
Wang X et al. Immunosuppression with a combination of pg490-88 and a subtherapeutic dose of FK506 in a canine renal allograft model. 2005 Transplantation pmid:15940043
Webb NJ et al. Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. 2015 Transplantation pmid:25539467
Günther M et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. 2001 Transplantation pmid:11233913
Veenhof H et al. Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. 2017 Transplantation pmid:27906832
Jin L et al. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. 2018 Transplantation pmid:29319618
Ekberg H et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. 2011 Transplantation pmid:21562449
Rayar M et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. 2018 Transplantation pmid:29315140
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Tourret J et al. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. 2017 Transplantation pmid:27681266
Kuypers DR et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. 2006 Transplantation pmid:16794545
Foster RD et al. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. 2003 Transplantation pmid:14508367
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098